for people ages 65 years and up (full criteria)
Healthy Volunteers
healthy people welcome
at San Francisco, California and other locations
study started
completion around
Principal Investigator
by Deborah Barnes, PhD
Headshot of Deborah Barnes
Deborah Barnes



The eRADAR Brain Health Study seeks to refine and test a novel, low-cost strategy for increasing dementia detection within primary care.

Official Title

Low-cost Detection of Dementia Using Electronic Health Records Data: Validation and Testing of the Electronic Health Record Risk of Alzheimer's and Dementia Assessment Rule (eRADAR) Algorithm in a Pragmatic, Patient-centered Trial.


Detailed description: eRADAR stands for "electronic health record (EHR) Risk of Alzheimer's and Dementia Assessment Rule." It is a low-cost tool or algorithm that uses readily available EHR data elements to identify high-risk patients. The investigators will conduct a pragmatic randomized controlled trial to assess the impact of implementing eRADAR as part of a supported outreach process on dementia detection rates. The investigators will also explore the impact of eRADAR implementation on healthcare utilization and patient experience.


Dementia, Alzheimer Disease, Brain Health Assessment


You can join if…

Open to people ages 65 years and up

  • No prior diagnosis of dementia (defined from EHR diagnosis codes) and not receiving medications for dementia
  • Active patient at participating clinic
  • Adequate data to calculate eRADAR score

You CAN'T join if...

- Currently receiving hospice care


  • UCSF Primary Care at China Basin not yet accepting patients
    San Francisco California 94107 United States
  • Women's Health Primary Care accepting new patients
    San Francisco California 94143 United States
  • Division of General Internal Medicine not yet accepting patients
    San Francisco California 94115 United States

Lead Scientist at UCSF

  • Deborah Barnes, PhD
    Dr. Barnes is internationally recognized as an expert in the epidemiology of dementia. There are currently more than 6 million Americans and 55 millions people worldwide living with Alzheimer's disease and related dementias, and prevalence is expected to more than double by 2050.


accepting new patients
Start Date
Completion Date
University of California, San Francisco
Study Type
Expecting 1350 study participants
Last Updated